Predictive factors of brain metastasis in patients with breast cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Xue, Jun ^a   Peng, Gang ^a   Yang, Jing Song ^b   Ding, Qian ^a   Cheng, Jing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Xiangfan Central Hospital   (China)

Author keywords

Brain metastases; Breast cancer; Logistic regression model; Receiver operator characteristic; Risk factors

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; BRAIN TUMOR; BREAST TUMOR; COHORT ANALYSIS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

ADULT; BRAIN NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, STATISTICAL; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84873465031     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0337-2     Document Type: Article

References (27)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62(4):220-41.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM, et al. Brain metastases. Curr Probl Surg. 2004;41(8):665-741.
4. Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 2006;7(6):479-89.
5. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev. 2007;26(3-4):635-43.
6. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol). 2004;16(5):345-9.
7. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-17.
8. Hayes DF. Prognostic and predictive factors for breast cancer: translating technology to oncology. J Clin Oncol. 2005;23(8):1596-7.
9. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15(11):1640-4.
10. Grewal J, Kesari S. Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis. Breast Cancer Res. 2008;10(2):104.
11. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer-Am Cancer Soc. 2006;107(4):696-704.
12. Ingle JN. Assessing the risk of recurrence in breast cancer. N Engl J Med. 1990;322(5):329-31.
13. Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2 + advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist. 2012;17(1):26-35.
14. Eccles SA, Paon L. Breast cancer metastasis: when, where, how? Lancet. 2005;365(9464):1006-7.
15. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-803.
16. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602.
17. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004;292(9):1064-73.
18. Devilee P, Rookus MA. A tiny step closer to personalized risk prediction for breast cancer. N Engl J Med. 2010;362(11):1043-5.
19. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23(28):7098-104.
20. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364(5):412-21.
21. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol. 2000;18(23):3925-35.
22. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, et al. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res. 2006;8(4):R36.
23. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol. 2003;14(7):1072-7.
24. Chargari C, Toillon RA, Macdermed D, Castadot P, Magne N. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol. 2009;10(1):53-60.
25. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502.
26. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16(3):439-43.
27. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499-505.